Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

Oncogene - 18 Mar 2010

Liang M-C, Ma J, Chen L, Kozlowski P, Qin W, Li D, Goto J, Shimamura T, Hayes D N, Meyerson M, Kwiatkowski D J, Wong K-K

Abstract excerpt

Germline TSC1 or TSC2 mutations cause tuberous sclerosis complex (TSC), a hamartoma syndrome with lung involvement. To explore the potential interaction between TSC1 and KRAS activation in lung cancer, mice in which Tsc1 loss and Kras(G12D) expression occur in a small fraction of lung epithelial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Bronchi
Share to In Situ Nick-End Labeling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Multiprotein Complexes

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Tuberous Sclerosis Complex 1 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 19966866
DOI: 10.1038/onc.2009.452
PMCID: PMC2841700

Genes

TSC1
TSC2
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19966866-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.PMID 19966866Read ↗

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.Semantic proximity Read ↗

PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung TumorigenesisSemantic proximity Read ↗

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.Semantic proximity Read ↗

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.Semantic proximity Read ↗

The dual role of the TSC complex in cancer.Semantic proximity Read ↗

Role of LKB1 in lung cancer development.Semantic proximity Read ↗

Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model.Semantic proximity Read ↗

The tuberous sclerosis complex genes in tumor development.Semantic proximity Read ↗

Hyperactivation of Mammalian Target of Rapamycin Complex 1 (mTORC1) Promotes Breast Cancer Progression through Enhancing Glucose Starvation-induced Autophagy and Akt SignalingSemantic proximity Read ↗

A dual role for autophagy in a murine model of lung cancer.Semantic proximity Read ↗

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.Semantic proximity Read ↗

Akt and mTORC1 have different roles during liver tumorigenesis in mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.